Impact of the Composition of Packed Red Blood Cell Supernatant on Renal

Status Completed

Clinical Trial Summary

Safety during transfusions is a major issue in medical economics. Despite drastic quality control measures, transfusion is still a source of short, mid and long-term morbi-mortality. This can be explained to some extent by changes in the composition of the packed red blood cell (PRBC) supernatant during storage essentially with the appearance of immunologically active compounds possibly involved in organ dysfunction on the one hand and post-transfusion immunomodulation on the other hand. These phenomena impact upon outcomes for cardiac surgery patients. In terms of organ dysfunction, kidney failure due to acute tubular necrosis and pulmonary failure are the 2 main issues. Following cardiac surgery, 11% of patients will present with transient renal dysfunction characterised by a 25% increase in serum creatinine levels and 3.5% require dialysis. The intensity of acute renal failure (ARF) is correlated to resuscitation : a 20% increase in serum creatinine levels 2 to 3 days after surgery significantly raises morbidity rates and a 50% increase raises the mortality rate to 10%. The precise mechanisms governing post-transfusion immunomodulation have not yet to be defined. The appearance of soluble type I Human leukocytes Antigen (HLA) molecules (sHLA-I), the FAS ligand (FAS-L) or cluster designation 40 (CD40-L) in the supernatant of PRBCs along the storage of blood products may be involved in such phenomena. These molecules are capable of activating or triggering the death of innate or adaptive immunity cells, especially the Natural Killer (NK) cells. Consequently the investigators propose to focus specifically on the detailed composition of transfused PRBC supernatants in order to identify the candidate molecules responsible for organ dysfunction or post-transfusion immunoparalysis. The investigators will combine a clinical approach based on the transcriptional analysis of renal tubular cells in transfused patients and an ex-vivo approach investigating the effect of the supernatant on immune cells and the Natural Killer cells of healthy volunteers

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02763410
Study type	Observational
Source	Nantes University Hospital
Contact
Status	Completed
Phase
Start date	September 8, 2016
Completion date	March 23, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03183245` - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis	Phase 3
Completed	`NCT04084301` - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury	N/A
Completed	`NCT03292029` - Pilot Medical Evaluation of the T50 Test	N/A
Suspended	`NCT04589065` - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)	N/A
Completed	`NCT03806998` - Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure	Phase 3
Active, not recruiting	`NCT03672110` - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen	Phase 3
Completed	`NCT02325726` - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.	N/A
Completed	`NCT02116270` - Accelerated Immunosenescence and Chronic Kidney Disease	N/A
Completed	`NCT01388270` - Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis	Phase 4
Completed	`NCT01859273` - Adherence Enhancement for Renal Transplant Patients	N/A
Completed	`NCT00966615` - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition	Phase 4
Completed	`NCT01187953` - Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx	Phase 3
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT01008631` - The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers	N/A
Completed	`NCT00765661` - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients	Phase 2
Completed	`NCT00737672` - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis	Phase 3
Completed	`NCT00808691` - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit	N/A
Recruiting	`NCT00470769` - The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR	N/A
Terminated	`NCT00338455` - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC	Phase 2
Completed	`NCT03917186` - Desflurane vs. Sevoflurane in Endovascular Aortic Repair	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation — TRANSNEPHRON

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms